61Curated trials
Enterprise Evidence Report · NR-REPORT-V2.0
Chile
Neuroscience Intelligence
Chile neuroscience evidence report: current clinical, research, institution and source-linked intelligence.
Evidence rank #36 of 50 · Data maturity A · Research score 30.9 · Data confidence 100.0 / 100 · Snapshot 2026-10-12 03:34 UTC.
16Recruiting trials
23Publications
20Institutions
Executive interpretation
Chile ranks #36 in the current NeuroRisk evidence-ranked market layer. This ranking summarizes indexed clinical, publication and institution evidence; it is not a probability of commercial success and not an investment recommendation.
Methodology status
Methodology NR-REPORT-V2.0. No synthetic ML confidence is presented as scientific probability. Counts and source links below are tied to the generation snapshot.
Methodology →Leading sponsors
Merck Sharp & Dohme LLC209 recruiting
Pfizer50 recruiting
GlaxoSmithKline30 recruiting
Hoffmann-La Roche30 recruiting
Pontificia Universidad Catolica de Chile30 recruiting
Xenon Pharmaceuticals Inc.21 recruiting
Novartis Pharmaceuticals20 recruiting
AbbVie20 recruiting
CanSino Biologics Inc.10 recruiting
Boehringer Ingelheim10 recruiting
Disease activity
Parkinsons21trials
Alzheimers7trials
Epilepsy5trials
Depression4trials
Anxiety3trials
Bipolar Disorder2trials
Pain Neuropathy2trials
Stroke2trials
Other Psychiatry2trials
Neuroimmunology1trials
Research institutions
Millennium Institute for Research in Depression and PersonalityOpenAlexlinked institution
Universidad Autónoma de ChileOpenAlexlinked institution
Universidad de Los Andes, ChileOpenAlexlinked institution
Instituto de Neurociencia BiomédicaOpenAlexlinked institution
Clínica AlemanaOpenAlexlinked institution
Universidad del DesarrolloOpenAlexlinked institution
Hospital Luis Calvo MackennaOpenAlexlinked institution
Centro de Recursos Educativos AvanzadosOpenAlexlinked institution
Universidad Técnica Federico Santa MaríaOpenAlexlinked institution
Centro de Estudios CientíficosOpenAlexlinked institution
Clinical evidence trail
NCT07611578Dual Tasking Training to Enhance Self-Efficacy in Individuals With Parkinson's DiseaseNOT_YET_RECRUITING
NCT07252739KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)RECRUITING
NCT07216703A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)RECRUITING
NCT06966700A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)RECRUITING
NCT06952504A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)RECRUITING
NCT06788912Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)RECRUITING
NCT06780085A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)RECRUITING
NCT06290128A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not WorkACTIVE_NOT_RECRUITING
NCT05980949Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)RECRUITING
NCT05973773REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)ACTIVE_NOT_RECRUITING
Research evidence trail
PUBMEDMetformin enhances hippocampal excitatory synaptic transmission and preserves synaptic plasticity under amyloid-β oligomer-induced dysfunction.2026-11-15
PUBMEDPressure Points: A Scoping Review of Intracranial Pressure and Mean Arterial Pressure Measurement and Reporting Practices in Neurocritical Care.2026-10-09
PUBMEDAcute Effects of Automated Peripheral Stimulation on Autonomic and Functional Capacity in Parkinson's Disease.2026-10-09
PUBMEDComparative analysis of the effects of Δ9-tetrahydrocannabinol and cannabidiol on pilocarpine-induced status epilepticus in mice.2026-10-06
PUBMEDDo Latino Populations Have a Distinct Pain Sensitivity? A Quantitative Sensory Testing Study in Chilean Healthy Volunteers.2026-10-01
PUBMEDPotential adverse effects of antipsychotics during pregnancy: A narrative review with a focus on metabolic alterations.2026-10-01
PUBMEDSelective impairment of long-term depression in accumbal D1R+ MSNs involves calcium-permeable AMPARs in early Alzheimer's disease.2026-10-01
PUBMEDClinical and audiovestibular findings in pediatric vestibular migraine spectrum disorders.2026-09-16
PUBMEDDrosophila melanogaster as a Model for Autism Spectrum Disorder: Insights into Lifelong Neuronal Vulnerability.2026-09-12
PUBMEDImpaired skin reinnervation in epidermolysis bullosa due to neurotrophic deficiency.2026-08-01
PUBMEDExercise preconditioning attenuates ischemic neurological deficits without modulating motor learning in a rodent model of focal cortical ischemia.2026-08-01
Sources and provenance
ClinicalTrials.gov provides NCT evidence. PubMed/NCBI and OpenAlex provide research metadata. OpenAlex links institutions. World Bank indicators are included only when an explicit source row and year exist. NeuroRisk transformations add normalization, ranking and graph connections.
Limitations
Indexed corpus counts are not guaranteed exhaustive global totals. Scores are comparative decision-support signals. This report is not medical advice, regulatory advice, patent clearance, an investment recommendation or a guarantee of outcome.